Acute Ischemic Stroke
Conditions
Brief summary
A multicenter, randomized, double-blind, parallel, placebo-controlled trial design is used to evaluate the efficacy and safety of GM1 injection in the treatment of patients with acute ischemic stroke. It is estimated that 1706 patients will be enrolled and randomly assigned to the treatment group and the placebo control group in a 1:1 ratio. Normally, the duration of this study is approximately 90 days. Treatment was continued for 12\ 14 days, and follow-up was conducted until the 90th day from the first dose. The trial is divided into three phases: screening/baseline phase, treatment phase, and follow-up phase. Screening/baseline period: After the subjects sign the informed consent form, they enter the screening/baseline period for screening examination. Treatment period: Qualified subjects are randomly divided into groups in a 1:1 ratio and receive continuous treatment for 12\ 14 days (12\ 14 times) with GM1 injection and placebo respectively. During the treatment period, relevant examinations and evaluations required by the protocol will be carried out. Follow-up period: Subjects who have completed treatment will enter the follow-up period until the 90th day of treatment.
Interventions
Monosialoganglioside diluted with 0.9% normal saline 100ml, iv, daily for 12-14 days
DRUGPlacebo
Placebo diluted with 0.9% normal saline 100ml, iv, daily for 12-14 days
Sponsors
Qilu Pharmaceutical Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Age: 18-80 years old； * Patients with anterior circulation cerebral infarction; first stroke onset or past stroke without obvious neurological deficit (mRS score≤1)； * Within 24 hours of onset； * 7 ≤NIHSS score ≤ 20； * Signed informed consent.
Exclusion criteria
* Patients with hereditary abnormal glucose and lipid metabolism (gangliosidosis, such as Tay-Sachs disease and retinal degeneration); * Hemorrhagic stroke; * Disturbance of consciousness (NIHSS1a≥1)，or cerebral arteritis, brain tumor, brain trauma, intracranial infectious diseases; * Planed endovascular treatment; * Uncontrolled hypertension: systolic pressure ≥200 mmHg or diastolic pressure ≥110 mmHg; * Bleeding tendency (except for thrombolysis) or severe bleeding within 3 months; * Patients with malignant tumor or serious diseases; * Along with epilepsy, arthritis and other disease, which have effect on neurological assessment; * History of autoimmune diseases, spinal trauma, various demyelinating diseases, including acute inflammatory demyelinating polyneuropathy (Guillain Barre syndrome); * Unable or unwilling to cooperate due to mental diseases; * Abnormal liver and renal function: ALT, AST \> 2 times of the upper limit of normal value, or Cr \> 1.5 times of the upper limit of normal value； * Hypersensitivity to monosialoganglioside and excipients of test drug; * History of drug abuse； * Pregnant or lactating women, pregnant plan or unwilling to use effective contraception during the trial period; * Participating in other clinical trials within 3 months; * Other conditions which are unsuitable for this trial assessed by researcher.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of modified Rankin Scale (mRS) 0-2 | 90 days | the minimum and maximum values of mRS are 0 and 6, respectively; higher mRS mean a worse outcome |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of modified Rankin Scale (mRS) 0-1 | 90 days | the minimum and maximum values of mRS are 0 and 6, respectively; higher mRS mean a worse outcome |
Countries
China
Outcome results
None listed